# RO4929097 in Treating Patients With Metastatic Colorectal Cancer

> **NCT01116687** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 37 (actual)

## Conditions studied

- Recurrent Colon Cancer
- Recurrent Rectal Cancer
- Stage IV Colon Cancer
- Stage IV Rectal Cancer

## Interventions

- **DRUG:** gamma-secretase/Notch signalling pathway inhibitor RO4929097
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT01116687
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05
- **Primary completion:** 2011-05
- **Final completion:** 2012-03
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2014-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01116687

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01116687, "RO4929097 in Treating Patients With Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT01116687. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*